Showing results (31-40 of 43) with videos related to
Sort By:
Pageof 5
Cancer|May 31, 2017
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokineticsAllyson J Ocean, Alexander N Starodub, Aditya Bardia, et al.Arthritis & Rheumatology (Hoboken, N.J.)|January 31, 2018
Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY TrialsJacques-Eric Gottenberg, Thomas Dörner, Hendrika Bootsma, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial resultsJohn P Leonard, Morton Coleman, Jamie C Ketas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2017
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal CancerEfrat Dotan, Steven J Cohen, Alexander N Starodub, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphomaFranck Morschhauser, Françoise Kraeber-Bodéré, William A Wegener, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2017
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab GovitecanRebecca Suk Heist, Michael J Guarino, Gregory Masters, et al.Cancer|May 10, 2012
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trialAllyson J Ocean, Kenneth L Pennington, Michael J Guarino, et al.The New England Journal of Medicine|February 21, 2019
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast CancerAditya Bardia, Ingrid A Mayer, Linda T Vahdat, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2017
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast CancerAditya Bardia, Ingrid A Mayer, Jennifer R Diamond, et al.The Lancet. Haematology|December 22, 2015
(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation studyPatrice Chevallier, Thomas Eugene, Nelly Robillard, et al.Pageof 5